Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Shire/New River NRP104 submission

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

Shire and New River are seeking a pediatric indication for children ages six to 12 for the attention deficit/hyperactivity disorder therapy NRP104. New River submitted an NDA for the amphetamine prodrug Dec. 6, giving FDA an Oct. 6, 2006 standard review action date. Lower abuse liability is one of the key advantages the sponsors hope to claim vis-à-vis currently marketed stimulant ADHD agents. The firms reported positive Phase III data for the new molecular entity in May (Pharmaceutical Approvals Monthly June 2005, In Brief)...

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

See All
UsernamePublicRestriction

Register

PS003156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By